短效β受体阻滞剂治疗脓毒症患者的死亡率:随机对照试验的综合Meta分析
该Meta分析纳入7项随机对照试验共854例成人脓毒症患者,评估静脉使用短效β受体阻滞剂(兰地洛尔或艾司洛尔)对短期死亡率的影响。结果显示,与对照治疗相比,短效β受体阻滞剂未显著影响短期死亡率及汇总死亡率(风险差-0.10,95%CI -0.22至0.02;p=0.11;Cochran Q检验p=0.001;I²=73%)。年龄<65岁与≥65岁患者间(p=0.11)、窦性心动过速与心房颤动患者间(p=0.27)均无差异。尽管存在统计学异质性,未观察到显著发表偏倚。作者认为短效β受体阻滞剂未降低持续心动过速脓毒症患者的短期死亡率,未来研究应提供广泛血流动力学数据以表征治疗前后的心脏功能。
要点
- 在成人脓毒症患者中,静脉使用短效β受体阻滞剂(兰地洛尔或艾司洛尔)与对照治疗相比,短期死亡率风险差为-0.10(95%CI -0.22至0.02),p=0.11,未达统计学显著。
- 汇总死亡率(最长随访期数据)同样未受短效β受体阻滞剂显著影响,合并分析异质性I²=73%(Cochran Q检验p=0.001)。
- 亚组分析显示,年龄<65岁与≥65岁患者间短期死亡率无差异(p=0.11);窦性心动过速与心房颤动患者间亦无差异(p=0.27)。
- 尽管存在统计学异质性,未观察到显著发表偏倚。
- 作者结论:短效β受体阻滞剂未降低持续心动过速脓毒症患者的短期死亡率;未来研究应提供广泛血流动力学数据以表征治疗前后的心脏功能。
适用人群与场景
- 成人脓毒症患者,纳入标准为随机对照研究且脓毒症分类有效、接受静脉短效β受体阻滞剂(兰地洛尔或艾司洛尔)治疗。
研究设计与关键结果
- 研究类型:随机对照试验的综合Meta分析,共纳入7项研究、854例患者。
- 干预与对照:静脉使用短效β受体阻滞剂(兰地洛尔或艾司洛尔) vs 参考治疗。
- 主要终点:短期死亡率风险差为-0.10(95%CI -0.22至0.02),p=0.11;Cochran Q检验p=0.001,I²=73%。
- 汇总死亡率(最长随访期数据)同样未受短效β受体阻滞剂显著影响(风险差-0.10,95%CI -0.22至0.02;p=0.11;Cochran Q检验p=0.001;I²=73%)。
- 亚组分析:年龄<65岁 vs ≥65岁患者短期死亡率无差异(p=0.11);窦性心动过速 vs 心房颤动患者无差异(p=0.27)。
- 未观察到显著发表偏倚。
证据类型、等级与局限
- 证据类型:随机对照试验的系统评价与Meta分析。
- 异质性:I²=73%,Cochran Q检验p=0.001。
- 未观察到显著发表偏倚。
- 局限:作者指出未来研究应提供广泛血流动力学数据以表征治疗前后的心脏功能。
对床旁实践的改变
- 作者认为,短效β受体阻滞剂未降低持续心动过速脓毒症患者的短期死亡率;未来研究应提供广泛血流动力学数据以表征治疗前后的心脏功能。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Treatment with short-acting betablockers in septic patients remains controversial. Two recent large multicenter trials have provided additional evidence on this therapeutic approach. We thus performed a meta-analysis, including the most recent data, to evaluate the potential impacts of treatment with short-acting betablockers on mortality in adult septic patients.
METHODS: The data search included PubMed, Web of Science, ClinicalTrials.gov and the Cochrane Library. A meta-analysis of all eligible peer-reviewed studies was performed in accordance with the PRISMA statement. Only randomized, controlled studies with valid classifications of sepsis and intravenous treatment with short-acting betablockers (landiolol or esmolol) were included. Short-term mortality served as the primary endpoint. Secondary endpoints included effects on short-term mortality regarding patient age and cardiac rhythm.
RESULTS: A total of seven studies summarizing 854 patients fulfilled the predefined criteria and were included. Short-term mortality as well as pooled mortality (longest period of data on mortality) was not significantly impacted by treatment with short-acting betablockers when compared to the reference treatment (Risk difference, - 0.10 [95% CI, - 0.22 to 0.02]; p = 0.11; p for Cochran's Q test = 0.001; I2 = 73%). No difference was seen when comparing patients aged < 65 versus ≥ 65 years (p = 0.11) or sinus tachycardia with atrial fibrillation (p = 0.27). Despite statistical heterogeneity, no significant publication bias was observed.
CONCLUSION: Administration of short-acting betablockers did not reduce short-term mortality in septic patients with persistent tachycardia. Future studies should also provide extensive hemodynamic data to enable characterization of cardiac function before and during treatment.
参考来源
- Alexandru MG, Niewald P, Krüger S, et al. Mortality in septic patients treated with short-acting betablockers: a comprehensive meta-analysis of randomized controlled trials. Crit Care. 2024. PMID: 39605034. doi:10.1186/s13054-024-05174-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。